{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:37:08Z","timestamp":1790613428574,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.yebeh.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T14:53:44Z","timestamp":1552920824000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy"],"prefix":"10.1016","volume":"94","author":[{"given":"Nobutsune","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.02.004_bb0005","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40263-012-0021-2","article-title":"Perampanel as adjunctive therapy in patients with partial-onset seizures","volume":"26","author":"Plosker","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0010","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures. Randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0020","first-page":"117","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0025","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306. Adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2017.08.014","article-title":"Effectiveness and tolerability of perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicenter study","volume":"52","author":"Swiderska","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology ckinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dmcn.13362","article-title":"Tolerability and efficacy of perampanel in children with refractory epilepsy","volume":"59","author":"Heyman","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2016.08.021","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsy\u2014An Italian observational multicenter study","volume":"127","author":"De Liso","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/epi.13981","article-title":"Comparative efficacy of antiepileptic drugs in children and adolescents: a network meta-analysis","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0b013e31820fa9ad","article-title":"Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication","volume":"32","author":"May","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0060","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0034-1387815","article-title":"Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy","volume":"45","author":"Wallander","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0070","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2016.10.013","article-title":"Evaluation of perampanel in patients with intellectual disability and epilepsy","volume":"66","author":"Snoeijen-Schouwenaars","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bcp.13400","article-title":"Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children","volume":"84","author":"Van Dijkman","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2019.02.004_bb0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019300599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019300599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:28:22Z","timestamp":1761503302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019300599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"alternative-id":["S1525505019300599"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.004","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}